Skip to content

ScaiDigest July 2023

ScaiDigest July 2023

ScaiDigest July 2023

ScaiDigest July 2023

We are excited to announce the launch of ScaiDigest, a regular scientific post that delves into the latest research papers in our field. 

In our inaugural edition, Diana Stoycheva, Principal Expert Scientist, shared interesting insights on the application of single-cell and multi-omics technologies to CAR T cell therapy.

“Application of Single-cell and multi-omics technologies in CAR T cell therapy

Chimeric antigen receptor (CAR) T cell therapy approaches have shown great potential to introduce a significant change to the treatment of cancer. However, the therapy’s full potential is yet to be unlocked as the scientific community is still learning about the intricacies of the mechanism of action, clinical implications and in vivo activity.


Single-cell and multi-omics approaches could be the key to unlocking the full potential of CAR T therapy and optimizing the therapy’s safety and efficacy as the approaches become more widely used. The full extent of using such approaches is highlighted in the works of Barboy et al. and Yang, Chen and Han.


The utilization of multi-omics data at single-cell resolution provides scientists with an immense amount of data which could be applied in different ways such as enhancing the efficacy of CAR T cell therapy, determining optimal CAR targets and minimizing the CAR T cell-related toxicities. Furthermore, the use of computational approaches, like machine learning and artificial intelligence, has been highlighted as the method of expediting the integration of multi-omics data in both discovery and clinical evaluation.”  

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10212274/

https://aacrjournals.org/cancerdiscovery/article-abstract/13/7/1546/727638/In-Synergy-Optimizing-CAR-T-Development-and

Stay tuned for more insightful posts in ScaiDigest, where we will continue to share  scientific advancements which excite us and their potential impact on healthcare.

About Scailyte

Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets. 

Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.

For more information, visit www.scailyte.com and connect on social media @LinkedIn and @Twitter.

ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG.

Recent News

Scailyte is fundraising!

Scailyte is kicking off its new fundraising campaign! We are seeking like-minded investors who share...

Read more

Recent News

Scailyte and Visterra Partner to Advance Autoimmune Disease Research

Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...

Read more

Recent News

Precision Medicine and The Future of Genomics Summit 2024

Scailyte at the Global Stage of Precision Medicine – PMFG 2024! We are proud to share that our CEO...

Read more

Recent News

Exploring Type 2 T Cell Immunity in Cancer—A Single-Cell Revolution

In this issue of ScaiDigest, we highlight two groundbreaking studies that expand the boundaries of i...

Read more

Recent News

Pitch Nic 2024 at Novartis Campus

We’re thrilled to announce that our CEO, Peter Nestorov will join the innovative minds at Pitch Ni...

Read more

Recent News

Genomics for Health 2024

Don't miss Scailyte's CEO, Peter Nestorov, at the Genomics for Health 2024 event, bridging cutting-e...

Read more

Recent News

The Year of the AI Nobel

2024 is being hailed as the "Year of the AI Nobel," marking a milestone as artificial intelligence (...

Read more

Recent News

01 /04

Scailyte is fundraising!

Scailyte is kicking off its new fundraising campaign! We are seeking like-minded investors who share...

Read more

Scailyte and Visterra Partner to Advance Autoimmune Disease Research

Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...

Read more

Recent News

02 /04

Precision Medicine and The Future of Genomics Summit 2024

Scailyte at the Global Stage of Precision Medicine – PMFG 2024! We are proud to share that our CEO...

Read more

Exploring Type 2 T Cell Immunity in Cancer—A Single-Cell Revolution

In this issue of ScaiDigest, we highlight two groundbreaking studies that expand the boundaries of i...

Read more

Recent News

03 /04

Pitch Nic 2024 at Novartis Campus

We’re thrilled to announce that our CEO, Peter Nestorov will join the innovative minds at Pitch Ni...

Read more

Recent News

04 /04

Genomics for Health 2024

Don't miss Scailyte's CEO, Peter Nestorov, at the Genomics for Health 2024 event, bridging cutting-e...

Read more

The Year of the AI Nobel

2024 is being hailed as the "Year of the AI Nobel," marking a milestone as artificial intelligence (...

Read more

Recent News